The company said total worldwide sales for Q1 2026 were $16,286 million, up 5% from $15,529 million a year earlier (3% excluding foreign exchange). KEYTRUDA/KEYTRUDA QLEX sales rose 12% to $8,034 million.

1. 01

   The company said total worldwide sales for Q1 2026 were $16,286 million, up 5% from $15,529 million a year earlier (3% excluding foreign exchange). KEYTRUDA/KEYTRUDA QLEX sales rose 12% to $8,034 million.

2. 02

   Merck said its GAAP loss per share for Q1 was $1.72 and its non-GAAP loss per share was $1.28, and that both include a charge of $3.62 per share related to the Cidara acquisition. The company cited the Cidara acquisition cost of $9.0 billion as a factor in higher R&D expenses.

3. 03

   The company said WINREVAIR sales for Q1 were $525 million, up 88% from $280 million a year earlier, and Animal Health sales rose 13% to $1,791 million.

4. 04

   The company provided its full-year 2026 worldwide sales outlook of $65.8 billion to $67.0 billion and non-GAAP EPS outlook of $5.04 to $5.16. The outlook does not reflect the Terns acquisition, and the company said the acquisition is expected to result in a one-time charge of approximately $5.8 billion.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.